Systematic Review on the Effectiveness of Immunosuppressants and Biological Therapies in the Treatment of Autoimmune Posterior Uveitis

Seminars in Arthritis and Rheumatism

Volumn 40, Issue 4, 2011, Pages 314-323

  Pato, Esperanza ^a   Muñoz Fernández, Santiago ^b   Francisco, Félix ^c   Abad, Miguel A ^d   Maese, Jesús ^e   Ortiz, Ana ^f   Carmona, Loreto ^g  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

^c HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^d HOSPITAL VIRGEN DEL PUERTO   (Spain)

^e Grupo SER de revisores   (Spain)

^f HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^g UNIDAD DE INVESTIGACIÓN   (Spain)

Author keywords

Biological therapies; Cystoid macular edema; Effectiveness; Immunosuppressants; Uveitis

Indexed keywords

ACETAZOLAMIDE; ADALIMUMAB; ALPHA2A INTERFERON; AZATHIOPRINE; BIOLOGICAL PRODUCT; CHLORAMBUCIL; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DACLIZUMAB; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERFERON; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RAPAMYCIN; TACROLIMUS;

ARTICLE; AUTOIMMUNE DISEASE; BEHCET DISEASE; BIOLOGICAL THERAPY; CHRONIC DISEASE; DRUG EFFICACY; DRUG WITHDRAWAL; EMBASE; EYE INFLAMMATION; HUMAN; HYPERTENSION; INTERMEDIATE UVEITIS; IRIDOCYCLITIS; JUVENILE RHEUMATOID ARTHRITIS; MEDLINE; POPULATION RESEARCH; PRIORITY JOURNAL; RETINA MACULA CYSTOID EDEMA; RETINA MACULA EDEMA; RETINA VASCULITIS; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY;

EID: 78751705747     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2010.05.008     Document Type: Article

References (169)

1. Yeh S., Faia L.J., Nussenblatt R.B. Advances in the diagnosis and immunotherapy for ocular inflammatory disease. Semin Immunopathol 2008, 30(2):145-164.
2. Suttorp-Schulten M.S., Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol 1996, 80(9):844-848.
3. Banares A., Jover J.A., Fernandez-Gutierrez B., Benitez del Castillo J.M., Garcia J., Vargas E., et al. Patterns of uveitis as a guide in making rheumatologic and immunologic diagnoses. Arthritis Rheum 1997, 40(2):358-370.
4. Jabs D.A., Rosenbaum J.T., Foster C.S., Holland G.N., Jaffe G.J., Louie J.S., et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2000, 130(4):492-513.
5. Lustig M.J., Cunningham E.T. Use of immunosuppressive agents in uveitis. Curr Opin Ophthalmol 2003, 14(6):399-412.
6. Kim E.C., Foster C.S. Immunomodulatory therapy for the treatment of ocular inflammatory disease: evidence-based medicine recommendations for use. Int Ophthalmol Clin 2006, 46(2):141-164.
7. Hogan M.J., Kimura S.J., Thygeson P. Signs and symptoms of uveitis. I. Anterior uveitis. Am J Ophthalmol 1959, 47(5 Part 2):155-170.
8. Jabs D.A., Nussenblatt R.B., Rosenbaum J.T. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005, 140(3):509-516.
9. Nussenblatt R.B., Palestine A.G., Chan C.C., Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 1985, 92(4):467-471.
10. BJU Int 2009, 104(11):1825. Oxford Centre for evidence-based medicine levels of evidence (May 2001).
11. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17(1):1-12.
12. BenEzra D., Cohen E., Chajek T., Friedman G., Pizanti S., de Courten C., et al. Evaluation of conventional therapy versus cyclosporine A in Behcet's syndrome. Transplant Proc 1988, 20(3 Suppl 4):136-143.
13. de Smet M.D., Rubin B.I., Whitcup S.M., Lopez J.S., Austin H.A., Nussenblatt R.B. Combined use of cyclosporine and ketoconazole in the treatment of endogenous uveitis. Am J Ophthalmol 1992, 113(6):687-690.
14. de Vries J., Baarsma G.S., Zaal M.J., Boen-Tan T.N., Rothova A., Buitenhuis H.J., et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. Br J Ophthalmol 1990, 74(6):344-349.
15. Masuda K., Nakajima A., Urayama A., Nakae K., Kogure M., Inaba G. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease. Lancet 1989, 1(8647):1093-1096.
16. Murphy C.C., Greiner K., Plskova J., Duncan L., Frost N.A., Forrester J.V., et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol 2005, 123(5):634-641.
17. Nussenblatt R.B., Palestine A.G., Chan C.C., Stevens G., Mellow S.D., Green S.B. Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. Am J Ophthalmol 1991, 112(2):138-146.
18. Nussenblatt R.B., de Smet M.D., Rubin B., Freidlin V., Whitcup S.M., Davis J., et al. A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin. Am J Ophthalmol 1993, 115(5):583-591.
19. Ramadan A.M., Nussenblatt R.B., de Smet M.D. Long-term follow-up of patients with chronic uveitis affecting the posterior pole treated with combination cyclosporine and ketoconazole. Ophthalmology 1997, 104(4):706-711.
20. Ozyazgan Y., Yurdakul S., Yazici H., Tuzun B., Iscimen A., Tuzun Y., et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Behcet's syndrome: a single masked trial. Br J Ophthalmol 1992, 76(4):241-243.
21. Araujo A.A., Wells A.P., Dick A.D., Forrester J.V. Early treatment with cyclosporin in serpiginous choroidopathy maintains remission and good visual outcome. Br J Ophthalmol 2000, 84(9):979-982.
22. BenEzra D., Cohen E., Rakotomalala M., de Courten C., Harris W., Chajek T., et al. Treatment of endogenous uveitis with cyclosporine A. Transplant Proc 1988, 20(3 Suppl 4):122-127.
23. Binder A.I., Graham E.M., Sanders M.D., Dinning W., James D.G., Denman A.M. Cyclosporin A in the treatment of severe Behcet's uveitis. Br J Rheumatol 1987, 26(4):285-291.
24. Caspers-Velu L.E., Decaux G., Libert J. Cyclosporine in Behcet's disease resistant to conventional therapy. Ann Ophthalmol 1989, 21(3):111-168.
25. Graham E.M., Sanders M.D., James D.G., Hamblin A., Kasp Grochowska E., Dumonde D. Cyclosporin A in the treatment of posterior uveitis. Trans Ophthalmol Soc UK 1985, 104(Pt 2):146-151.
26. Le Hoang P., Girard B., Deray G., Le Minh H., De Kozak Y., Thillaye B., et al. Cyclosporine in the treatment of birdshot retinochoroidopathy. Transplant Proc 1988, 20(3 Suppl 4):128-130.
27. Ozdal P.C., Ortac S., Taskintuna I., Firat E. Long-term therapy with low dose cyclosporin A in ocular Behcet's disease. Doc Ophthalmol 2002, 105(3):301-312.
28. Pacor M.L., Biasi D., Lunardi C., Cortina P., Caramaschi P., Girelli D., et al. Cyclosporin in Behcet's disease: results in 16 patients after 24 months of therapy. Clin Rheumatol 1994, 13(2):224-227.
29. Palestine A.G., Nussenblatt R.B., Gelato M. Therapy for human autoimmune uveitis with low-dose cyclosporine plus bromocriptine. Transplant Proc 1988, 20(3 Suppl 4):131-135.
30. Sajjadi H., Soheilian M., Ahmadieh H., Hassanein K., Parvin M., Azarmina M., et al. Low dose cyclosporin-A therapy in Behcet's disease. J Ocul Pharmacol 1994, 10(3):553-560.
31. Secchi A.G., Tognon M.S., Maselli C. Cyclosporine-A in the treatment of serpiginous choroiditis. Int Ophthalmol 1990, 14(5-6):395-399.
32. Secchi A.G., De Rosa C., Pivetti-Pezzi P., Rossi A., De Molfetta V., Tognon S., et al. Open noncontrolled multicenter long-term trial with ciclosporin in endogenous non-infectious uveitis. Ophthalmologica 1991, 202(4):217-224.
33. Sullu Y., Oge I., Erkan D., Ariturk N., Mohajeri F. Cyclosporin-A therapy in severe uveitis of Behcet's disease. Acta Ophthalmol Scand 1998, 76(1):96-99.
34. Towler H.M., Cliffe A.M., Whiting P.H., Forrester J.V. Low dose cyclosporin A therapy in chronic posterior uveitis. Eye 1989, 3(Pt 3):282-287.
35. Towler H.M., Whiting P.H., Forrester J., et al. Combination low dose cyclosporin a and steroid therapy in chronic intraocular inflammation. Eye 1990, 4(3):514-520.
36. Towler H.M., Lightman S.L., Forrester J.V. Low-dose cyclosporin therapy of ocular inflammation: preliminary report of a long-term follow-up study. J Autoimmun 1992, 5(Suppl A):259-264.
37. Agarwal M., Ganesh S.K., Biswas J. Triple agent immunosuppressive therapy in Vogt-Koyanagi-Harada syndrome. Ocul Immunol Inflamm 2006, 14(6):333-339.
38. Atmaca L.S., Batioglu F. The efficacy of cyclosporin-a in the treatment of Behcet's disease. Ophthalmic Surg 1994, 25(5):321-327.
39. Dees C., Arnold J.J., Forrester J.V., Dick A.D. Immunosuppressive treatment of choroidal neovascularization associated with endogenous posterior uveitis. Arch Ophthalmol 1998, 116(11):1456-1461.
40. Dios Castro E., Herreras Cantalapiedra J.M., Calonge Cano M., Oses S. Ocular sarcoidosis. Retrospective study of 18 cases. Arch Soc Esp Oftalmol 2002, 77(6):301-308.
41. Hakin K.N., Pearson R.V., Lightman S.L. Sympathetic ophthalmia: visual results with modern immunosuppressive therapy. Eye 1992, 6(Pt 5):453-455.
42. Hayasaka S., Kawamoto K., Noda S., Kodama T. Visual prognosis in patients with Behcet's disease receiving colchicine, systemic corticosteroid or cyclosporin. Ophthalmologica 1994, 208(4):210-213.
43. Kilmartin D.J., Forrester J.V., Dick A.D. Cyclosporin A therapy in refractory non-infectious childhood uveitis. Br J Ophthalmol 1998, 82(7):737-742.
44. Kiss S., Ahmed M., Letko E., Foster C.S. Long-term follow-up of patients with birdshot retinochoroidopathy treated with corticosteroid-sparing systemic immunomodulatory therapy. Ophthalmology 2005, 112(6):1066-1071.
45. Menezo V., Lau C., Comer M., Lightman S. Clinical outcome of chronic immunosuppression in patients with non-infectious uveitis. Clin Exp Ophthalmol 2005, 33(1):16-21.
46. Michel S.S., Ekong A., Baltatzis S., Foster C.S. Multifocal choroiditis and panuveitis: immunomodulatory therapy. Ophthalmology 2002, 109(2):378-383.
47. Muftuoglu A.U., Pazarli H., Yurdakul S., Yazici H., Ulku B.Y., Tuzun Y., et al. Short term cyclosporin A treatment of Behcet's disease. Br J Ophthalmol 1987, 71(5):387-390.
48. Nussenblatt R.B., Palestine A.G., Rook A.H., Scher I., Wacker W.B., Gery I. Treatment of intraocular inflammatory disease with cyclosporin A. Lancet 1983, 30(2(8344):235-238.
49. Nussenblatt R.B., Palestine A.G., Chan C.C. Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am J Ophthalmol 1983, 96(3):275-282.
50. Paredes I., Ahmed M., Foster C.S. Immunomodulatory therapy for Vogt-Koyanagi-Harada patients as first-line therapy. Ocul Immunol Inflamm 2006, 14(2):87-90.
51. Pascalis L., Pia G., Aresu G., Frongia T., Barca L. Combined cyclosporin A-steroid-MTX treatment in endogenous non-infectious uveitis. J Autoimmun 1993, 6(4):467-480.
52. Vitale A.T., Rodriguez A., Foster C.S. Low-dose cyclosporine therapy in the treatment of birdshot retinochoroidopathy. Ophthalmology 1994, 101(5):822-831.
53. Vitale A.T., Rodriguez A., Foster C.S. Low-dose cyclosporin A therapy in treating chronic, noninfectious uveitis. Ophthalmology 1996, 103(3):365-373.
54. Wakefield D., McCluskey P. Cyclosporine: a therapy in inflammatory eye disease. J Ocul Pharmacol 1991, 7(3):221-226.
55. Walton R.C., Nussenblatt R.B., Whitcup S.M. Cyclosporine therapy for severe sight-threatening uveitis in children and adolescents. Ophthalmology 1998, 105(11):2028-2034.
56. Whitcup S.M., Salvo E.C.J., Nussenblatt R.B. Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behcet's disease. Am J Ophthalmol 1994, 118(1):39-45.
57. Yu E.N., Meniconi M.E., Tufail F., Baltatzis S., Foster C.S. Outcomes of treatment with immunomodulatory therapy in patients with corticosteroid-resistant juvenile idiopathic arthritis-associated chronic iridocyclitis. Ocul Immunol Inflamm 2005, 13(5):353-360.
58. Mochizuki M., Masuda K., Sakane T., Inaba G., Ito K., Kogure M., et al. A multicenter clinical open trial of FK 506 in refractory uveitis, including Behcet's disease. Japanese FK 506 Study Group on Refractory Uveitis. Transplant Proc 1991, 23(6):3343-3346.
59. Mochizuki M., Masuda K., Sakane T., Ito K., Kogure M., Sugino N., et al. A clinical trial of FK506 in refractory uveitis. Am J Ophthalmol 1993, 115(6):763-769.
60. Figueroa M.S., Ciancas E., Orte L. Long-term follow-up of tacrolimus treatment in immune posterior uveitis. Eur J Ophthalmol 2007, 17(1):69-74.
61. Ishioka M., Ohno S., Nakamura S., Isobe K., Watanabe N., Ishigatsubo Y., et al. FK506 treatment of noninfectious uveitis. Am J Ophthalmol 1994, 118(6):723-729.
62. Sloper C.M., Powell R.J., Dua H.S. Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology 1999, 106(4):723-728.
63. Hogan A.C., McAvoy C.E., Dick A.D., Lee R.W. Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. Ophthalmology 2007, 114(5):1000-1006.
64. Kilmartin D.J., Forrester J.V., Dick A.D. Tacrolimus (FK506) in failed cyclosporin A therapy in endogenous posterior uveitis. Ocul Immunol Inflam 1998, 6(2):101-109.
65. Davatchi F., Shahram F., Chams H., Jamshidi A.R., Nadji A., Chams C., et al. High dose methotrexate for ocular lesions of Behcet's disease. Preliminary short-term results. Adv Exp Med Biol 2003, 528:579-584.
66. Dev S., McCallum R.M., Jaffe G.J. Methotrexate treatment for sarcoid-associated panuveitis. Ophthalmology 1999, 106(1):111-118.
67. Foeldvari I., Wierk A. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol 2005, 32(2):362-365.
68. Kaplan-Messas A., Barkana Y., Avni I., Neumann R. Methotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritis. Ocul Immunol Inflamm 2003, 11(2):131-139.
69. Lazar M., Weiner M.J., Leopold I.H. Treatment of uveitis with methotrexate. Am J Ophthalmol 1969, 67(3):383-387.
70. Malik A.R., Pavesio C. The use of low dose methotrexate in children with chronic anterior and intermediate uveitis. Br J Ophthalmol 2005, 89(7):806-808.
71. Samson C.M., Waheed N., Baltatzis S., Foster C.S. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology 2001, 108(6):1134-1139.
72. Shetty A.K., Zganjar B.E., Ellis G.S.J., Ludwig I.H., Gedalia A. Low-dose methotrexate in the treatment of severe juvenile rheumatoid arthritis and sarcoid iritis. J Pediatr Ophthalmol Strabismus 1999, 36(3):125-128.
73. Soheilian M., Aletaha M., Yazdani S., Dehghan M.H., Peyman G.A. Management of pediatric Vogt-Koyanagi-Harada (VKH)-associated panuveitis. Ocul Immunol Inflamm 2006, 14(2):91-98.
74. Weiss A.H., Wallace C.A., Sherry D.D. Methotrexate for resistant chronic uveitis in children with juvenile rheumatoid arthritis. J Pediatr 1998, 133(2):266-268.
75. Mathews J.D., Crawford B.A., Bignell J.L., Mackay I.R. Azathioprine in active chronic iridocyclitis. A double-blind controlled trial. Br J Ophthalmol 1969, 53(5):327-330.
76. Yazici H., Pazarli H., Barnes C.G., Tuzun Y., Ozyazgan Y., Silman A., et al. A controlled trial of azathioprine in Behcet's syndrome. N Engl J Med 1990, 322(5):281-285.
77. Andrasch R.H., Pirofsky B., Burns R.P. Immunosuppressive therapy for severe chronic uveitis. Arch Ophthalmol 1978, 96(2):247-251.
78. Bietti G.B., Cerulli L., Pivetti-Pezzi P. Behcet's disease and immunosuppressive treatment. Our personal experience Mod Probl Ophthalmol 1976, 16:314-323.
79. Cuchacovich M., Pacheco P., Diaz G., Rojas B., Stoppel J., Merino G., et al. Role of Azathioprine in steroid resistant non infectious ocular inflammatory diseases. Rev Med Chil 2007, 135(6):702-707.
80. Hamuryudan V., Ozyazgan Y., Hizli N., Mat C., Yurdakul S., Tuzun Y., et al. Azathioprine in Behcet's syndrome: effects on long-term prognosis. Arthritis Rheum 1997, 40(4):769-774.
81. Schatz C.S., Uzel J.L., Leininger L., Danner S., Terzic J., Fischbach M. Immunosuppressants used in a steroid-sparing strategy for childhood uveitis. J Pediatr Ophthalmol Strabismus 2007, 44(1):28-34.
82. Vianna R.N., Ozdal P.C., Deschenes J., Burnier M.N.J. Combination of azathioprine and corticosteroids in the treatment of serpiginous choroiditis. Can J Ophthalmol 2006, 41(2):183-189.
83. Kilmartin D.J., Forrester J.V., Dick A.D. Rescue therapy with mycophenolate mofetil in refractory uveitis. Lancet 1998, 352(9121):35-36.
84. Larkin G., Lightman S. Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease. Ophthalmology 1999, 106(2):370-374.
85. Doycheva D., Deuter C., Stuebiger N., Biester S., Zierhut M. Mycophenolate mofetil in the treatment of uveitis in children. Br J Ophthalmol 2007, 91(2):180-184.
86. Lau C.H., Comer M., Lightman S. Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation. Clin Exp Ophthalmol 2003, 31(6):487-491.
87. Siepmann K., Huber M., Stubiger N., Deuter C., Zierhut M. Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis a retrospective analysis of 106 patients. Graefes Arch Clin Exp Ophthalmol 2006, 244(7):788-794.
88. Thorne J.E., Jabs D.A., Qazi F.A., Nguyen Q.D., Kempen J.H., Dunn J.P. Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology 2005, 112(8):1472-1477.
89. Abdalla M.I., el-D Bahoat N. Long-lasting remission of Behcet's disease after chlorambucil therapy. Br J Ophthalmol 1973, 57(9):706-711.
90. Godfrey W.A., Epstein W.V., O'Connor G.R., Kimura S.J., Hogan M.J., Nozik R.A. The use of chlorambucil in intractable idiopathic uveitis. Am J Ophthalmol 1974, 78(3):415-428.
91. Tessler H.H., Jennings T. High-dose short-term chlorambucil for intractable sympathetic ophthalmia and Behcet's disease. Br J Ophthalmol 1990, 74(6):353-357.
92. Akpek E.K., Jabs D.A., Tessler H.H., Joondeph B.C., Foster C.S. Successful treatment of serpiginous choroiditis with alkylating agents. Ophthalmology 2002, 109(8):1506-1513.
93. Elliott J.H., Ballinger W.H. Behcet's syndrome: treatment with chlorambucil. Trans Am Ophthalmol Soc 1984, 82:264-281.
94. Jennings T., Tessler H.H. Twenty cases of sympathetic ophthalmia. Br J Ophthalmol 1989, 73(2):140-145.
95. Miserocchi E., Baltatzis S., Ekong A., Roque M., Foster C.S. Efficacy and safety of chlorambucil in intractable noninfectious uveitis: the Massachusetts Eye and Ear Infirmary experience. Ophthalmology 2002, 109(1):137-142.
96. Mudun B.A., Ergen A., Ipcioglu S.U., Burumcek E.Y., Durlu Y., Arslan M.O. Short-term chlorambucil for refractory uveitis in Behcet's disease. Ocul Immunol Inflamm 2001, 9(4):219-229.
97. O'Duffy J.D., Robertson D.M., Goldstein N.P. Chlorambucil in the treatment of uveitis and meningoencephalitis of Behcet's disease. Am J Med 1984, 76(1):75-84.
98. Tricoulis D. Treatment of Behcet's disease with chlorambucil. Br J Ophthalmol 1976, 60(1):55-57.
99. Durrani K., Papaliodis G.N., Foster C.S. Pulse IV cyclophosphamide in ocular inflammatory disease: efficacy and short-term safety. Ophthalmology 2004, 111(5):960-965.
100. Suhler E.B., Smith J.R., Wertheim M.S., Lauer A.K., Kurz D.E., Pickard T.D., et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 2005, 123(7):903-912.
101. Abu El-Asrar A.M., Abboud E.B., Aldibhi H., Al-Arfaj A. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behcet's disease. Int Ophthalmol 2005, 26(3):83-92.
102. Accorinti M., Pirraglia M.P., Paroli M.P., Priori R., Conti F., Pivetti-Pezzi P. Infliximab treatment for ocular and extraocular manifestations of Behcet's disease. Jpn J Ophthalmol 2007, 51(3):191-196.
103. Arayssi T, Hamra R, Homeidan F, Uthman I, Awwad ST, Mroue K, et al. The efficacy of a single dose of infliximab in the treatment of Behcet's disease uveitis. Clin Exp Rheumatol 427;23(3):427.
104. Benitez-del-Castillo J.M., Martinez-de-la-Casa J.M., Pato-Cour E., Mendez-Fernandez R., Lopez-Abad C., Matilla M., et al. Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab). Eye 2005, 19(8):841-845.
105. Cobo-Ibanez T., Munoz-Fernandez S., Hidalgo-Barrero V., Martin-Mola E. Medium-long term treatment with infliximab and methotrexate in posterior and/or chronic uveitis refractory to conventional treatment. Med Clin (Barc) 2006, 126(1):34-35. 14.
106. Foeldvari I., Nielsen S., Kummerle-Deschner J., Espada G., Horneff G., Bica B., et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol 2007, 34(5):1146-1150.
107. Joseph A., Raj D., Dua H.S., Powell P.T., Lanyon P.C., Powell R.J. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 2003, 110(7):1449-1453.
108. Lindstedt E.W., Baarsma G.S., Kuijpers R.W., van Hagen P.M. Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol 2005, 89(5):533-536.
109. Markomichelakis N.N., Theodossiadis P.G., Pantelia E., Papaefthimiou S., Theodossiadis G.P., Sfikakis P.P. Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol 2004, 138(4):648-650.
110. Merino G., Varas G., Diaz G., Gutierrez M., Massardo L., Pacheco D., et al. Effectiveness of infliximab in patients with Behcet syndrome and severe uveoretinitis. Report of five cases. Rev Med Chil 2006, 134(7):875-882.
111. Nakamura S., Ohno S. Anti-tumor necrosis factor alpha antibody in the treatment of Behcet's disease. Int Ophthalmol Clin 2005, 45(2):179-189.
112. Niccoli L., Nannini C., Benucci M., Chindamo D., Cassara E., Salvarani C., et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study. Rheumatology (Oxford) 2007, 46(7):1161-1164.
113. Sfikakis P.P., Kaklamanis P.H., Elezoglou A., Katsilambros N., Theodossiadis P.G., Papaefthimiou S., et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet disease. Ann Intern Med 2004, 140(5):404-406.
114. Sfikakis P.P., Theodossiadis P.G., Katsiari C.G., Kaklamanis P., Markomichelakis N.N. Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet 2001, 358(9278):295-296.
115. Tugal-Tutkun I., Mudun A., Urgancioglu M., Kamali S., Kasapoglu E., Inanc M., et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet's disease: an open-label trial. Arthritis Rheum 2005, 52(8):2478-2484.
116. Bodaghi B., Bui Quoc E., Wechsler B., Tran T.H., Cassoux N., Le Thi Huong D., et al. Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors. Ann Rheum Dis 2005, 64(6):962-964.
117. Galor A., Perez V.L., Hammel J.P., Lowder C.Y. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 2006, 113(12):2317-2323.
118. Gallagher M., Quinones K., Cervantes-Castaneda R.A., Yilmaz T., Foster C., et al. Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol 2007, 91(10):1341-1344.
119. Kahn P., Weiss M., Imundo L.F., Levy D.M. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology 2006, 113(5):860-864.e2.
120. Lanthier N., Parc C., Scavennec R., Dhote R., Brezin A.P., Guillevi L., et al. Infliximab in the treatment of posterior uveitis in behcet's disease: long term follow up in four patients. Presse Med 2005, 34(13):916-918.
121. Murphy C.C., Ayliffe W.H., Booth A., Makanjuola D., Andrews P.A., Jayne D. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 2004, 111(2):352-356.
122. Rajaraman R.T., Kimura Y., Li S., Haines K., Chu D.S. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology 2006, 113(2):308-314.
123. Richards J.C., Tay-Kearney M.L., Murray K., Manners P. Infliximab for juvenile idiopathic arthritis-associated uveitis. Clin Exp Ophthalmol 2005, 33(5):461-468.
124. Saurenmann R.K., Levin A.V., Rose J.B., Parker S., Rabinovitch T., Tyrrell P.N., et al. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology (Oxford) 2006, 45(8):982-989.
125. Sharma S.M., Ramanan A.V., Riley P., Dick A.D. Use of infliximab in juvenile onset rheumatological disease-associated refractory uveitis: efficacy in joint and ocular disease. Ann Rheum Dis 2007, 66(6):840-841.
126. Smith J.R., Levinson R.D., Holland G.N., Jabs D.A., Robinson M.R., Whitcup S.M., et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 2001, 45(3):252-257.
127. Sobrin L., Kim E.C., Christen W., Papadaki T., Letko E., Foster C.S. Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol 2007, 125(7):895-900.
128. Tynjala P., Lindahl P., Honkanen V., Lahdenne P., Kotaniemi K. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2007, 66(4):548-550.
129. Wechsler B., Sable-Fourtassou R., Bodaghi B., Huong D.L., Cassoux N., Badelon I., et al. Infliximab in refractory uveitis due to Behcet's disease. Clin Exp Rheumatol 2004, 22(4 Suppl 34):S14-S16.
130. Foster C.S., Tufail F., Waheed N.K., Chu D., Miserocchi E., Baltatzis S., et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 2003, 121(4):437-440.
131. Smith J.A., Thompson D.J., Whitcup S.M., Suhler E., Clarke G., Smith S., et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005, 53(1):18-23.
132. Reiff A., Takei S., Sadeghi S., Stout A., Shaham B., Bernstein B., et al. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 2001, 44(6):1411-1415.
133. Biester S., Deuter C., Michels H., Haefner R., Kuemmerle-Deschner J., Doycheva D., et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 2007, 91(3):319-324.
134. Vazquez-Cobian L.B., Flynn T., Lehman T.J. Adalimumab therapy for childhood uveitis. J Pediatr 2006, 149(4):572-575.
135. Mushtaq B., Saeed T., Situnayake R.D., Murray P.I. Adalimumab for sight-threatening uveitis in Behcet's disease. Eye 2007, 21(6):824-825.
136. Buggage R.R., Levy-Clarke G., Sen H.N., Ursea R., Srivastava S.K., Suhler E.B., et al. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behcet's disease. Ocul Immunol Inflamm 2007, 15(2):63-70.
137. Nussenblatt R.B., Fortin E., Schiffman R., Rizzo L., Smith J., Van Veldhuisen P., et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci USA 1999, 96(13):7462-7466.
138. Nussenblatt R.B., Peterson J.S., Foster C.S., Rao N.A., See R.F., Letko E., et al. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology 2005, 112(5):764-770.
139. Nussenblatt R.B., Thompson D.J., Li Z., Chan C.C., Peterson J.S., Robinson R.R., et al. Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun 2003, 21(3):283-293.
140. Hernandez Garfella M.L., Diaz Llopis M., Salom Alonso D., Cervera Taulet E. Recurrent uveitis and therapy with monoclonal antibody (daclizumab). Arch Soc Esp Oftalmol 2004, 79(12):593-598.
141. Papaliodis G.N., Chu D., Foster C.S. Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology 2003, 110(4):786-789.
142. Deuter C.M., Koetter I., Guenaydin I., Stuebiger N., Zierhut M. Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis?. A pilot study. Retina 2006, 26(7):786-791.
143. Hamuryudan V., Ozyazgan Y., Fresko Y., Mat C., Yurdakul S., Yazici H. Interferon alfa combined with azathioprine for the uveitis of Behcet's disease: an open study. Isr Med Assoc J 2002, 4(11 Suppl):928-930.
144. Pivetti-Pezzi P., Accorinti M., Pirraglia M.P., Priori R., Valesini G. Interferon alpha for ocular Behcet's disease. Acta Ophthalmol Scand 1997, 75(6):720-722.
145. Plskova J., Greiner K., Forrester J.V. Interferon-alpha as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol 2007, 144(1):55-61.
146. Sobaci G., Bayraktar Z., Bayer A. Interferon alpha-2a treatment for serpiginous choroiditis. Ocul Immunol Inflamm 2005, 13(1):59-66.
147. Becker M.D., Heiligenhaus A., Hudde T., Storch-Hagenlocher B., Wildemann B., Barisani-Asenbauer T., et al. Interferon as a treatment for uveitis associated with multiple sclerosis. Br J Ophthalmol 2005, 89(10):1254-1257.
148. Bodaghi B., Gendron G., Wechsler B., Terrada C., Cassoux N., Huong du L.T., et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol 2007, 91(3):335-339.
149. Calguneri M., Ozturk M.A., Ertenli I., Kiraz S., Apras S., Ozbalkan Z. Effects of interferon alpha treatment on the clinical course of refractory Behcet's disease: an open study. Ann Rheum Dis 2003, 62(5):492-493.
150. Guillaume-Czitrom S., Berger C., Pajot C., Bodaghi B., Wechsler B., Kone-Paut I. Efficacy and safety of interferon-alpha in the treatment of corticodependent uveitis of paediatric Behcet's disease. Rheumatology (Oxford) 2007, 46(10):1570-1573.
151. Tugal-Tutkun I., Guney-Tefekli E., Urgancioglu M. Results of interferon-alfa therapy in patients with Behcet uveitis. Graefes Arch Clin Exp Ophthalmol 2006, 244(12):1692-1695.
152. Kotter I., Gunaydin I., Zierhut M., Stubiger N. The use of interferon alpha in Behcet disease: review of the literature. Semin Arthritis Rheum 2004, 33(5):320-335.
153. Alpsoy E., Durusoy C., Yilmaz E., Ozgurel Y., Ermis O., Yazar S., et al. Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol 2002, 138(4):467-471.
154. Farber M.D., Lam S., Tessler H.H., Jennings T., Cross A., Rusin M.M. Reduction of macular oedema by acetazolamide in patients with chronic iridocyclitis: a randomised prospective crossover study. Br J Ophthalmol 1994, 78(1):4-7.
155. Lashay A.R., Rahimi A., Chams H., Davatchi F., Shahram F., Hatmi Z.N., et al. Evaluation of the effect of acetazolamide on cystoid macular oedema in patients with Behcet's disease. Eye 2003, 17(6):762-766.
156. Whitcup S.M., Csaky K.G., Podgor M.J., Chew E.Y., Perry C.H., Nussenblatt R.B. A randomized, masked, cross-over trial of acetazolamide for cystoid macular edema in patients with uveitis. Ophthalmology 1996, 103(7):1054-1062.
157. Cox S.N., Hay E., Bird A.C. Treatment of chronic macular edema with acetazolamide. Arch Ophthalmol 1988, 106(9):1190-1195.
158. Kotter I., Eckstein A.K., Stubiger N., Zierhut M. Treatment of ocular symptoms of Behcet's disease with interferon alpha 2a: a pilot study. Br J Ophthalmol 1998, 82(5):488-494.
159. Kotter I., Zierhut M., Eckstein A.K., Vonthein R., Ness T., Gunaydin I., et al. Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol 2003, 87(4):423-431.
160. Murphy C.C., Greiner K., Plskova J., Duncan L., Frost A., Isaacs J.D., et al. Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis. Arch Ophthalmol 2004, 122(6):845-851.
161. Tehrani N.N., Saeed T., Murray P.I. Deep intramuscular methylprednisolone for the treatment of cystoid macular oedema in uveitis. Eye 2000, 14(Pt 5):691-694.
162. Zierhut M., Thiel H.J., Schlote T. Treatment of uveitic macular edema with acetazolamide. Doc Ophthalmol 1999, 97(3-4):409-413.
163. Schilling H., Heiligenhaus A., Laube T., Bornfeld N., Jurklies B. Long-term effect of acetazolamide treatment of patients with uveitic chronic cystoid macular edema is limited by persisting inflammation. Retina 2005, 25(2):182-188.
164. Wakefield D., McCluskey P., Penny R. Intravenous pulse methylprednisolone therapy in severe inflammatory eye disease. Arch Ophthalmol 1986, 104:847-851.
165. Kacmaz R.O., Kempen J.H., Newcomb C., Daniel E., Gangaputra S., Nussenblatt R.B., et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology 2010, 117(3):576-584.
166. Gangaputra S., Newcomb C.W., Liesegang T.L., Kacmaz R.O., Jabs D.A., Levy-Clarke G.A., et al. Methotrexate for ocular inflammatory diseases. Ophthalmology 2009, 116(11):2188-2198.
167. Pasadhika S., Kempen J.H., Newcomb C.W., Liesegang T.L., Pujari S.S., Rosenbaum J.T., et al. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol 2009, 148(4):500-509.
168. Daniel E., Thorne J.E., Newcomb C.W., Pujari S.S., Kacmaz R.O., Levy-Clarke G.A., et al. Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol 2010, 149(3):423-432.
169. Pujari S.S., Kempen J.H., Newcomb C.W., Gangaputra S., Daniel E., Suhler E.B., et al. Cyclophosphamide for ocular inflammatory diseases. Ophthalmology 2010, 117(2):356-365.